If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.28    -0.03 (-2.33%)
Bid:
1.23
Ask:
1.29
Spread: 0.06 (4.878%)
Market Cap: £30.03m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Product Launch

16 Dec 2005 07:00

Provexis PLC16 December 2005 PROVEXIS PLC ("Provexis" or the "Company") UK Launch of Sirco(TM) Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, is delighted to confirm the launch of itsSirco(TM) heart health juice drink in the UK in January 2006. The Company has so far secured an initial distribution base with two of the fivelargest supermarket retailers in the UK, which for reasons of commercialconfidentiality cannot be named at present. Both retailers will distributeSirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)will be initially available in premier stores which represent, by weighteddistribution, approximately 35 per cent. of their total UK distribution base.Within the second supermarket chain, Sirco(TM) will be initially available, byweighted distribution, across 70 per cent. of their total UK distribution base.Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,Apple & Blueberry and Orange, and the drink will be located in the chilled fruitjuice section. The Company is in on-going discussions with a number of other retailers andhopes to make further distribution announcements in 2006. In addition to the onelitre packs, the Company is also developing a 250ml bottle of Sirco(TM) fordistribution to retailers in mid 2006. This bottle will have an extended shelflife and is intended to widen the distribution base to include independentchemists, convenience stores and food service industry channels such as health,education and travel outlets. Sirco(TM) is the first heart health product to contain the patentedFruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order tohelp regular "healthy" consumers reduce the risk of heart attack and stroke. Thenatural bioactive works by reducing blood platelet aggregation ("thinning theblood"), a significant contributing factor to a thrombosis (internal bloodclot). Sirco(TM) carries the health claim "Helps to Maintain a Healthy Heart andBenefits Circulation" and is approved by the leading heart health charity, HEARTUK. Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said: "This marks a significant milestone for Provexis and we are delighted that wehave secured distribution with two of the largest UK supermarkets. Bothretailers are ideal outlets in terms of the demographics and target market forthis product. We will be investing in media advertising as well as in-storeactivity to ensure we maximise this substantial opportunity. We look forward to growing the retailer base for Sirco(TM) throughout 2006,whilst in parallel securing licensing arrangements with major international foodpartners to integrate the FruitFlow(TM) technology into new food products inglobal markets." For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jun 20174:35 pmRNSPrice Monitoring Extension
19th May 20174:40 pmRNSSecond Price Monitoring Extn
19th May 20174:35 pmRNSPrice Monitoring Extension
10th May 20177:01 amRNSTrading Update
10th May 20177:00 amRNSResults of Placing
2nd May 20177:15 amRNSFunding Update
11th Apr 20174:40 pmRNSSecond Price Monitoring Extn
11th Apr 20174:35 pmRNSPrice Monitoring Extension
6th Apr 20177:00 amRNSBy-Health MOU and product launch for Fruitflow
8th Feb 20174:40 pmRNSSecond Price Monitoring Extn
8th Feb 20174:35 pmRNSPrice Monitoring Extension
30th Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:41 pmRNSSecond Price Monitoring Extn
21st Dec 20164:35 pmRNSPrice Monitoring Extension
20th Dec 20167:00 amRNSFruitflow and Blood Pressure - second stage update
23rd Nov 20167:00 amRNSStudy publication - comparison with aspirin
18th Nov 20169:46 amRNSNew Collaboration for Fruitflow
30th Sep 20163:33 pmRNSResult of AGM
15th Sep 20165:08 pmRNSDirector/PDMR Shareholding
7th Sep 20167:00 amRNSPreliminary Results
2nd Sep 201610:23 amRNSHolding(s) in Company
2nd Aug 20167:00 amRNSResults of Placing
12th Jul 20167:00 amRNSStudy Publication
29th Jun 20167:05 amRNSFunding Update
29th Jun 20167:00 amRNSProduct Launch
9th Jun 20162:29 pmRNSFunding Update
31st May 20167:00 amRNSTrading Update
11th Apr 20164:40 pmRNSSecond Price Monitoring Extn
11th Apr 20164:35 pmRNSPrice Monitoring Extension
25th Feb 20164:40 pmRNSSecond Price Monitoring Extn
25th Feb 20164:35 pmRNSPrice Monitoring Extension
19th Feb 20164:40 pmRNSSecond Price Monitoring Extn
19th Feb 20164:35 pmRNSPrice Monitoring Extension
7th Jan 20162:01 pmRNSDirector/PDMR Shareholding
22nd Dec 20157:00 amRNSHalf Yearly Report
30th Sep 20154:58 pmRNSResult of AGM
7th Sep 201510:47 amRNSAnnual Report and Notice of AGM
4th Sep 20157:00 amRNSPreliminary Results
21st Jul 20153:41 pmRNSHolding(s) in Company
3rd Jul 20157:00 amRNSPlacing of shares via Primarybid.com
29th Jun 20157:00 amRNSUpdate of Collaboration with University of Oslo
4th Jun 20157:00 amRNSEnhanced terms for Fruitflow Alliance Agreement
24th Apr 20154:35 pmRNSPrice Monitoring Extension
20th Feb 20152:34 pmRNSFruitflow - New Product Video
19th Jan 20154:40 pmRNSSecond Price Monitoring Extn
19th Jan 20154:35 pmRNSPrice Monitoring Extension
30th Dec 20147:00 amRNSHalf Yearly Report
9th Dec 20147:00 amRNSDraw Down of Funds and Issue of Equity
1st Dec 20147:00 amRNSRe-appointment to the Scientific Advisory Board
18th Nov 20147:00 amRNSCollaboration with the University of Oslo

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.